GSK plc (NYSE: GSK) Stock Competitors & Peer Comparison

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while LLY trades at $1,179.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas LLY's P/E ratio is 37.15. In terms of profitability, GSK's ROE is +0.24%, compared to LLY's ROE of +0.93%. Regarding short-term risk, GSK is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for GSK.Check LLY's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, JNJ has a market cap of 618B. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while JNJ trades at $261.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas JNJ's P/E ratio is 23.90. In terms of profitability, GSK's ROE is +0.24%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, GSK is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for GSK.Check JNJ's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, ABBV has a market cap of 481.4B. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while ABBV trades at $276.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas ABBV's P/E ratio is 26.74. In terms of profitability, GSK's ROE is +0.24%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, GSK is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for GSK.Check ABBV's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, MRK has a market cap of 351.7B. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while MRK trades at $145.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas MRK's P/E ratio is 44.36. In terms of profitability, GSK's ROE is +0.24%, compared to MRK's ROE of +0.07%. Regarding short-term risk, GSK is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for GSK.Check MRK's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, NVS has a market cap of 272B. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while NVS trades at $143.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas NVS's P/E ratio is 16.47. In terms of profitability, GSK's ROE is +0.24%, compared to NVS's ROE of +0.30%. Regarding short-term risk, GSK is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for GSK.Check NVS's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, AZN has a market cap of 246.2B. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while AZN trades at $159.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas AZN's P/E ratio is 17.14. In terms of profitability, GSK's ROE is +0.24%, compared to AZN's ROE of +0.22%. Regarding short-term risk, GSK is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for GSK.Check AZN's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, AMGN has a market cap of 219.9B. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while AMGN trades at $414.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas AMGN's P/E ratio is 18.21. In terms of profitability, GSK's ROE is +0.24%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, GSK is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for GSK.Check AMGN's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, GILD has a market cap of 182.4B. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while GILD trades at $151.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas GILD's P/E ratio is -377.18. In terms of profitability, GSK's ROE is +0.24%, compared to GILD's ROE of -0.16%. Regarding short-term risk, GSK is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for GSK.Check GILD's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, NVO has a market cap of 169.4B. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while NVO trades at $38.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas NVO's P/E ratio is 9.49. In terms of profitability, GSK's ROE is +0.24%, compared to NVO's ROE of +0.59%. Regarding short-term risk, GSK is less volatile compared to NVO. This indicates lower risk in terms of short-term price fluctuations for GSK.Check NVO's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, PFE has a market cap of 158.7B. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while PFE trades at $28.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas PFE's P/E ratio is 9.13. In terms of profitability, GSK's ROE is +0.24%, compared to PFE's ROE of +0.05%. Regarding short-term risk, GSK is less volatile compared to PFE. This indicates lower risk in terms of short-term price fluctuations for GSK.Check PFE's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, BMY has a market cap of 121.7B. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while BMY trades at $59.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas BMY's P/E ratio is 10.04. In terms of profitability, GSK's ROE is +0.24%, compared to BMY's ROE of +0.47%. Regarding short-term risk, GSK is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for GSK.Check BMY's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, SNY has a market cap of 96.6B. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while SNY trades at $40.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas SNY's P/E ratio is 8.76. In terms of profitability, GSK's ROE is +0.24%, compared to SNY's ROE of +0.06%. Regarding short-term risk, GSK is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for GSK.Check SNY's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, BIIB has a market cap of 32.3B. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while BIIB trades at $225.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas BIIB's P/E ratio is 13.79. In terms of profitability, GSK's ROE is +0.24%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, GSK is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for GSK.Check BIIB's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while HZNP trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas HZNP's P/E ratio is 61.86. In terms of profitability, GSK's ROE is +0.24%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, GSK is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for GSK.Check HZNP's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, GRFS has a market cap of 6.3B. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while GRFS trades at $7.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas GRFS's P/E ratio is 8.51. In terms of profitability, GSK's ROE is +0.24%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, GSK is less volatile compared to GRFS. This indicates lower risk in terms of short-term price fluctuations for GSK.Check GRFS's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while OGN trades at $13.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas OGN's P/E ratio is 4.11. In terms of profitability, GSK's ROE is +0.24%, compared to OGN's ROE of +0.23%. Regarding short-term risk, GSK is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for GSK.Check OGN's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, AMRN has a market cap of 248M. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while AMRN trades at $12.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas AMRN's P/E ratio is -119.90. In terms of profitability, GSK's ROE is +0.24%, compared to AMRN's ROE of -0.06%. Regarding short-term risk, GSK is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for GSK.Check AMRN's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, MIRA has a market cap of 29.5M. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while MIRA trades at $0.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas MIRA's P/E ratio is -0.48. In terms of profitability, GSK's ROE is +0.24%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, GSK is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for GSK.Check MIRA's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, SCLX has a market cap of 25.1M. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while SCLX trades at $2.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas SCLX's P/E ratio is -0.08. In terms of profitability, GSK's ROE is +0.24%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, GSK is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for GSK.Check SCLX's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, SCLXW has a market cap of 21M. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while SCLXW trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas SCLXW's P/E ratio is N/A. In terms of profitability, GSK's ROE is +0.24%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, GSK is more volatile compared to SCLXW. This indicates higher risk in terms of short-term price fluctuations for GSK.Check SCLXW's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while BDSIW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, GSK's ROE is +0.24%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, GSK is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for GSK.Check BDSIW's competition here

GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GSK stands at 93.2B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, GSK is priced at $46.50 on the NYSE, while CRXT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GSK currently has a P/E ratio of 10.05, whereas CRXT's P/E ratio is -0.02. In terms of profitability, GSK's ROE is +0.24%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, GSK is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for GSK.Check CRXT's competition here